Phosphonium ion channel blockers and methods for use

A compound represented by Formula (I)

• wherein
• Y− is a pharmaceutically acceptable anion;
• RB is selected from —C(O)OCH3 and —C(O)OCH2CH3;
• each of RD and RE is independently selected from H, 2H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, and substituted or unsubstituted cycloalkyl;
• or RD and RE together with the carbon to which they are attached form a substituted or unsubstituted C3-C6 cycloalkyl, or a substituted or unsubstituted 5- to 10-membered heterocyclic;
• each of RF, RG and RH is independently selected from H, 2H, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted —C6-C10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted —CH2-C6-C10 aryl, and substituted or unsubstituted —CH2-5- to 10-membered heteroaryl;
• or, two or three of RF, RG and RH together with the P+ to which they are attached form an optionally substituted 5- to 10-membered heterocyclic ring having, zero, one or more heteroatoms in addition to the P+;
• or two or three of RD, RE, RF, RG and RH together with the P+ form an optionally substituted 5- to 10-membered heterocyclic ring having, zero, one or more heteroatoms in addition to the P+.